Similar findings were observed in group VI compared to groups V and IV (3 years 26.3% vs. 66.7% and 90%, and 16.3% vs. 25.6% and 51%, respectively) when the co-expression of BRD4 and PD-1 were used to predict OS in AML (p < 0.001, Figures 2A,B, lower panel). Here, BRD4 is linked to acute myeloid leukemia.